The Evolving Castration-Resistant Prostate Cancer Treatment Landscape
Mathew R. Smith, MD, PhD closes the discussion by sharing clinical pearls for community oncologists and highlights unmet needs in the CRPC landscape.
The Use of Darolutamide in Patients with Castration-Resistant Prostate Cancer
Dr. Smith presents key data concerning the use of darolutamide in patients with castration-resistant CRPC, with a focus on safety and patient quality of life.
Reviewing the Standard of Care for Patients with Nonmetastatic Castration-Resistant Disease
Expert panelist provides his perspective on a CRPC patient case before discussing the typical course of treatment for patients with nonmetastatic CRPC.
A 57-Year-Old Man with Nonmetastatic Castration-Resistant Disease
Matthew R. Smith, MD, PhD introduces a nonmetastatic castration-resistant prostate cancer (CRPC) patient case featuring a 52-year-old man referred to urology with a PSA of 6.8 ng/mL.
Unmet Needs and Key Takeaways in mCRPC
Matthew R. Smith, MD, PhD, discusses areas of unmet needs and clinical pearls for the management of patients with mCRPC.
Treatment Options Upon Progression on ADT
Prostate cancer expert Dr Smith elaborates on treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on systemic therapy.
Experience with Darolutamide in Clinical Practice
Matthew R. Smith, MD, PhD, shares his personal experience using darolutamide for patients with prostate cancer.
Next Generation Androgen Receptor Inhibitors
Dr Matthew Smith discusses next generation androgen receptor inhibitors and data from clinical trials with these agents.
The Role of Molecular Testing in mCRPC
Prostate cancer expert, Matthew R. Smith, MD, PhD, shares his thoughts about importance of testing in treatment of metastatic castration-resistant prostate cancer (mCRPC).
Initial Treatment Options for mCRPC
Dr Matthew R. Smith reviews initial treatment options for a patient with metastatic castration-resistant prostate cancer (mCRPC).
mCRPC: Monitoring Patients
An expert in prostate cancer discusses the typical follow-up and monitoring approaches for a patient with metastatic CRPC.
Case Overview: 82-Year-Old Man With Metastatic CRPC
Matthew R. Smith, MD, PhD, presents the case of a 82-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and shares his initial impressions.
Novel Hormonal Agents Show Significant Benefits in Patients With mCRPC
Matthew Smith, MD, PhD, discussed the new hormone therapies entering the treatment landscape for metastatic castration-resistant prostate cancer.
2 Clarke Drive Cranbury, NJ 08512